Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative. SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617. The SOLAR trial aimed to evaluate the safety and biodistribution of Copper Cu 64 PSMA I&T to detect prostate cancer. 18F-DCFPyL imaging has impacted clinical decision-making of treatment management for patients with prostate cancer. PSMA PET imaging is a leap forward in the fight to cure prostate cancer, especially as theranostic capabilities expand. Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL. 68Ga-PSMA-11 and FDG-PET/CT scans were compared with scans from the VISION trial to assess patient eligibility for Pluvicto. The care management plans for several patients were changed after those patients underwent PSMA PET/CT. A research team developed a study to implement aPROMISE for the evaluation of PSMA and FDG-PET/CT scans acquired before RLT. The proposed method of algorithm-based TTV produced comparable TTV and whole-body SUVmean levels. Researchers compared the performance of Ga-68 PSMA PET/CT vs F-18-NaF PET/CT in detecting bone metastases in prostate cancer. An encoder-decoder network employing 3-dimensional convolutions was trained to segment regions that were suspected of cancer. Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC. The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress. 64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose. POSLUMA is a diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer. A newly developed prognostic risk score had a good model fit for predicting OS in internal and external validation cohorts. When testing interaction with the use of MDT, patients with positive PSMA PET not receiving MDT had a higher risk of CR. Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward. Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.